Ann: Appendix 4E - Preliminary Final Report, page-20

Unfortunately I am the other way around, wish it was otherwise BUT CXL total in my portfolio is quickly over taking this dog.

I guess in hindsight the difference is the patents & diversity. FLC really have no IP worth squat as MABR is open tech, they have just tweaked some stuff. Hopefully it will get some more product sold but as I have said many times USA & Europe are where the reliable $$ will be but FLC don't seem interested or capable of selling there IMO FLC's product is just not good enough to make it in these markets, otherwise they would have been building sales there.

Yep negative for sure, just another very unhappy investor but hey that's the market & learn from your mistakes.
.